Martin Auster
Stock Analyst at Raymond James
(3.93)
# 600
Out of 5,150 analysts
54
Total ratings
58.14%
Success rate
10.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Strong Buy | $40 | $23.88 | +67.50% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $28.13 | +35.09% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $64.53 | +10.03% | 2 | Oct 30, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $64.36 | +67.81% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $239.22 | +13.28% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $14.60 | +139.73% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $318.65 | +33.06% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $58.53 | +105.02% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $22.07 | +375.76% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $7.87 | +230.37% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $5.96 | +1,913.42% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $725 → $300 | $28.08 | +968.38% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $33.78 | +71.70% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $498.65 | -60.69% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $2.07 | +4,634.30% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $147.00 | -59.18% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $44.31 | +46.69% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $15.87 | +359.99% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $9.03 | +763.79% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.91 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.50 | +405.88% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $13.61 | +54.36% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $52.83 | -69.71% | 1 | May 7, 2020 |
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $23.88
Upside: +67.50%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $28.13
Upside: +35.09%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $64.53
Upside: +10.03%
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $64.36
Upside: +67.81%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $239.22
Upside: +13.28%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $14.60
Upside: +139.73%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $318.65
Upside: +33.06%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $58.53
Upside: +105.02%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $22.07
Upside: +375.76%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $7.87
Upside: +230.37%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $5.96
Upside: +1,913.42%
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $28.08
Upside: +968.38%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $33.78
Upside: +71.70%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $498.65
Upside: -60.69%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $2.07
Upside: +4,634.30%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $147.00
Upside: -59.18%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $44.31
Upside: +46.69%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $15.87
Upside: +359.99%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $9.03
Upside: +763.79%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.91
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.50
Upside: +405.88%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $13.61
Upside: +54.36%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $52.83
Upside: -69.71%